Drug makers don't oppose generic drug legislation

By Gloria Galloway, Globe and Mail

Canada's brand-name drug companies say they do not object to an NDP private-member's bill aimed at unblocking efforts to make cheap generic versions of lifesaving drugs available to the world's poor.

In a letter sent last week to all parties in the House of Commons, Russell Williams, the president of Canada's Research-Based Pharmaceutical Companies (R&D), said his organization "will not oppose the amendments proposed in Bill C-398," provided that any reforms to Canada's Access to Medicines Regime (CAMR) comply with World Trade Organization rules.

That is good news to Hélène Laverdière, the New Democratic sponsor of the bill, who says international legal experts agree that there is nothing in her proposed legislation that would contravene WTO agreements.

For the rest of the article, please click here.